New Perspectives on Biologic Therapy in Moderate-to-Severe Ulcerative Colitis

New Perspectives on Biologic Therapy in Moderate-to-Severe Ulcerative Colitis is organized by Omnia Education.

Released:  09/13/2019
Valid until: 09/13/2020

Accreditation:
Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.

Overview:
Advancements in the treatment of ulcerative colitis (UC) have given us the ability to control patient symptoms, achieve inflammation control, prolong remission, and prevent disease progression. Join Dr. David Rubin as he discusses how biologic therapies and small molecule DMARDs play a role in the UC treatment paradigm.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Translate emerging and real-world data on comparative efficacy and safety of anti-integrins and anti-TNFs to treatment planning
• Understand the disease activity index and prognosis as an independent factor in determining treatment

Additional details will be posted as soon as information is available.